

# Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.  
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2020-21/032

November 12, 2020

To,

Listing Department

**BSE Ltd**

1<sup>st</sup> Floor, New Trade Wing,

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai - 400 001.

**Scrip Code: 532637**

Listing Department

**National Stock Exchange of India Limited**

"Exchange Plaza", 5<sup>th</sup> Floor,

Plot No. C-1, Block G,

Bandra - Kurla Complex,

Bandra(E), Mumbai - 400 051

**Symbol: MANGALAM**

**Sub: Outcome of the Board Meeting held on Thursday, November 12, 2020**

Dear Sir / Madam,

In terms of Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (the Listing Regulations), we have to inform you that the Board of Directors of the Company, in their meeting held today i.e. Thursday, November 12, 2020 has *inter-alia* approved the Un-Audited Financial Results on Standalone basis for the quarter and half year ended September 30, 2020 along with the Limited Review Report on the results pursuant to Regulation 33 of the Listing Regulations.

The meeting of Board of Directors commenced at 11:00 A.M. and concluded at 2:10 P.M.

We request you to take the same on your records.

Thanking You,

Yours faithfully,

For Mangalam Drugs & Organics Limited

**Govardhan M. Dhoot**  
Chairman & Managing Director  
DIN: 01240086

**Standalone Un-Audited Financial Results for the Half Year Ended 30th September 2020 approved and taken on record by the Board at their meeting dated 12th November, 2020**

Sr.No	Particulars	Quarter Ended			Half Year Ended		(Rs. In Lacs)
		30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
<b>A) Part-1 Statement of Un-Audited Financial Results for the Half Year Ended September 30, 2020</b>							
1	Revenue from Operations	9,702.57	10,364.06	6,727.31	20,066.63	13,231.54	28,235.36
2	Other Income	68.42	65.48	3.02	133.90	6.89	118.12
3	Total Revenue(1+2)	9,770.99	10,429.54	6,730.33	20,200.53	13,238.43	28,353.48
4	Expenses						
	(a) Cost of Materials Consumed	7,859.07	6,919.36	4,566.24	14,778.42	8,783.18	17,807.14
	(b) Purchase of Stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in Inventories of, Finished Goods and Stock-in-trade & Work In Progress	(1,765.02)	383.59	57.02	(1,381.43)	235.11	1,727.66
	(d) Employee Benefits Expenses	713.17	686.63	658.60	1,399.80	1,263.47	2,604.41
	(e) Finance Costs	260.42	215.80	274.60	476.22	539.73	1,040.47
	(f) Depreciation & amortization expenses	226.54	206.10	226.50	432.64	406.42	821.78
	(g) Other Expenses	1,133.26	1,012.76	833.39	2,146.02	1,792.24	3,726.81
	Total Expenses	8,427.44	9,424.23	6,616.36	17,851.67	13,020.15	27,728.27
5	Profit / (Loss) before exceptional & extraordinary items and tax(3-4)	1,343.55	1,005.31	113.97	2,348.86	218.28	625.21
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before extraordinary items and tax (5-6)	1,343.55	1,005.31	113.97	2,348.86	218.28	625.21
8	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit(+)/Loss (-) before tax(7-8)	1,343.55	1,005.31	113.97	2,348.86	218.28	625.21
10	Tax Expenses						
	Current Tax	384.86	185.09	33.18	569.95	63.56	110.10
	Mat Credit Entitlement	(150.01)	(9.33)	-0.00	(159.34)	0.00	(104.74)
	Deferred Tax	0.00	0.00	0.00	0.00	0.00	(205.40)
11	Net Profit(+)/Loss(-) after Tax (9-10)	1,108.70	829.55	80.79	1,938.25	154.72	825.25
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	(59.87)	(6.99)	0.61	(66.86)	1.13	2.32
13	Total Comprehensive Income	1,048.83	822.56	81.40	1,871.39	155.85	827.57
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity				10,682.44	8,139.33	8,811.05
16	Earnings Per Share (EPS) (of Rs 10/-each not annualised):						
	(a) Basic	7.00	5.24	0.51	12.25	0.98	5.21
	(b) Diluted	7.00	5.24	0.51	12.25	0.98	5.21

**Notes :**

- The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read together with Companies (Indian Accounting Standard) Rules, 2015.
- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on November 12, 2020. The Statutory Auditors have expressed an unmodified audit opinion on these financial result.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
- The Code on Social Security, 2020 ("Code") relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.
- Deferred Tax calculation as per Ind AS 12 is considered by the Company on annual basis
- Earlier period figures have been regrouped/ rearranged wherever necessary.

Place: Mumbai  
Date: 12th November, 2020




On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

Shri Govardhan M. Dhoot  
Chairman & Managing Director  
DIN:01240086

Statement of Assets and Liabilities		
	Rs. in Lacs	
	As at 30.09.2020 Unaudited	As at 31.03.2020 Audited
<b>ASSETS</b>		
<b>A. Non-current Assets</b>		
(a) Property, Plant and Equipment	9419.63	9329.20
(b) Capital Work-In-Progress	531.48	124.03
(c) Intangible assets	592.24	613.59
(d) Right to use assets	322.53	164.13
<b>(e) Financial Assets</b>		
(i) Investments	22.35	22.35
(ii) Other Financial Assets	239.33	236.18
(iii) Deferred Tax Asset (Net)		
(f) Non Current Tax Assets (Net)		
(g) Other Non-current Assets	274.17	659.75
<b>Total Non-current Assets (A)</b>	<b>11401.74</b>	<b>11,149.23</b>
<b>B. Current Assets</b>		
(a) Inventories	7175.68	6484.27
<b>(b) Financial Assets</b>		
(i) Trade Receivables	5726.02	3998.29
(ii) Cash and Cash Equivalents	96.90	162.91
(iii) Bank Balance other than Cash and Cash Equivalents		
(iv) Loans	1.69	0.96
(v) Others Financial Assets		
(c) Other Current Assets	1426.18	1271.04
<b>Total Current Assets (B)</b>	<b>14426.47</b>	<b>11,917.48</b>
<b>TOTAL ASSETS</b>	<b>25828.20</b>	<b>23,066.71</b>
<b>EQUITY AND LIABILITIES</b>		
<b>A. Equity</b>		
(a) Equity Share Capital	1582.82	1582.82
(b) Other Equity	10682.44	8811.05
<b>Total Equity (A)</b>	<b>12265.26</b>	<b>10,393.87</b>
<b>B. Non-Current Liability</b>		
<b>(a) Financial Liabilities</b>		
(i) Borrowings	536.45	417.28
(b) Deferred Tax Liabilities (Net)	1228.76	1228.76
(c) Lease Liability	174.89	80.05
(d) Deposits Taken	0.05	0.05
(e) Provisions		
(f) Other Non-Current Liabilities		
<b>Total Non-current Liabilities (B)</b>	<b>1940.15</b>	<b>1,726.13</b>
<b>C. Current Liabilities</b>		
<b>(a) Financial Liabilities</b>		
(i) Borrowings	3933.77	4186.08
(ii) Lease Liability	183.99	113.54
(ii) Trade Payables		
Payable to MSME	624.21	243.31
Others	5370.17	5416.03
(iii) Other Financial Liabilities	434.44	400.40
(b) Other Current Liabilities	643.70	504.78
(c) Provisions	432.51	82.56
<b>Total Current Liabilities (C)</b>	<b>11622.79</b>	<b>10,946.70</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>25828.20</b>	<b>23,066.71</b>

Notes:- 1) Previous periods/years figures have been regrouped/rearranged wherever necessary.

Place: Mumbai  
Date: 12th November 2020



On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

Shri Govardhan M. Dhoot  
Chairman & Managing Director  
DIN:01240086

**MANGALAM DRUGS AND ORGANICS LIMITED**

**Cash Flow Statement For The Period Ended September 30, 2020**

(Rupees In Lacs)

Particulars	For the Period ended September 30, 2020 Unaudited	For the Period ended March 31, 2020 Audited
<b>A. Cash flow from operating activities</b>		
<b>Net profit before tax and extra ordinary items.</b>	2,348.86	625.21
<b>Add / (Less) :</b>		
Depreciation & amortisation	432.64	821.78
Interest expenses	476.22	1,040.47
Dividend Income	-	(0.04)
(Gain)/loss on sale of fixed assets	1.62	5.36
(Gain)/loss on sale of investments		
Net gain arising on financial assets measured at fair value through profit or loss		
Remeasurements of the defined benefit plans	(66.86)	3.22
<b>Operating profit before working capital changes</b>	<b>3,192.48</b>	<b>2,496.00</b>
<b>Adjustment for :</b>		
(Increase)/decrease in short term loans and advances	(0.73)	(0.09)
(Increase)/decrease in other current assets	(155.14)	(19.68)
(Increase)/decrease in trade receivables	(1,727.72)	(2,235.22)
(Increase)/decrease in inventory	(691.42)	861.05
(Increase)/decrease in other non-current assets	382.42	(657.55)
Increase/(decrease) in Other Equity		
Increase/(decrease) in trade payables	335.04	2,417.99
Increase/(decrease) in other current liabilities	172.96	212.66
Increase/(decrease) in provisions	349.95	23.46
Increase/(decrease) in current lease liabilities	70.45	76.24
Increase/(decrease) in deposits	0.00	0.05
Increase/(decrease) in non current lease liabilities	94.84	(114.85)
	<b>(1,169.35)</b>	<b>564.07</b>
<b>Cash generated from operations</b>	<b>2,023.13</b>	<b>3,060.07</b>
<b>Add / ( Less) :</b>		
Income Tax (Paid)/ Refund	(410.61)	(5.36)
<b>Net cash from operating activities</b>	<b>1,612.52</b>	<b>3,054.71</b>
<b>B. Cash flow from investing activities :</b>		
Purchase of fixed assets including Capital WIP	(1,072.40)	(693.20)
Sale of fixed assets	3.22	4.24
Sale/(Purchase) of investments	-	1.66
Divided Income	-	0.04
<b>Net cash from investing activities</b>	<b>(1,069.18)</b>	<b>(687.26)</b>
<b>C. Cash flow from financing activities :</b>		
Proceeds/(repayment) of short term borrowing	(252.31)	(865.12)
Proceeds/(repayment) of long term borrowing	119.18	(442.28)
Interest Paid	(476.22)	(1,040.47)
Dividend paid	-	-
Issue of Share		
<b>Net cash used in financing activities</b>	<b>(609.35)</b>	<b>(2,347.88)</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>(66.01)</b>	<b>19.57</b>
<b>Cash and cash equivalents - opening balance</b>	<b>162.91</b>	<b>143.34</b>
<b>Cash and cash equivalents - closing balance</b>	<b>96.90</b>	<b>162.91</b>
<b>Details of cash and cash equivalent at the end of the Period / Year</b>		
- Cash in hand	4.46	6.48
- Balance in current & fixed deposit accounts	92.45	156.43
<b>Total</b>	<b>96.90</b>	<b>162.91</b>

Notes:- 1) Previous periods/years figures have been regrouped/rearranged wherever necessary.



On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

Shri Govardhan M.Dhoot  
Chairman & Managing Director  
DIN:01240086

Place: Mumbai  
Date: 12th November, 2020

**Limited Review Report on Unaudited Quarterly and Half Yearly Standalone Financial Results of Mangalam Drugs & Organics Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

TO THE BOARD OF DIRECTORS OF  
**Mangalam Drugs & Organics Limited**

We have reviewed the accompanying Statement of unaudited standalone financial results of **Mangalam Drugs & Organics Limited** ("Company") for the quarter and half year ended 30<sup>th</sup> Sep 2020 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed, under Section 133 of the Companies Act, 2013, and accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to the financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Emphasis of Matter**

Securities and Exchange Board of India (SEBI) has passed an order dated September 22, 2020 inter-alia alleging certain compliance/ disclosure lapses on the part of the Company in relation to preferential allotment of warrants to one of the promoter group entities which were undertaken in September 2015. In terms of this order, the Company and certain entities/ individuals part of the promoter group have been restrained from accessing the securities market through issue of securities or subscription to securities, directly or indirectly for a period of 6 months and certain monetary penalties have been imposed on each of them. The Company and certain entities / individuals part of the promoter and promoter group has filed an Appeal before the Hon'ble Securities Appellate Tribunal on November 6, 2020 against the order passed by SEBI and prayed for suitable reliefs and /or stay orders.

Our opinion is not modified in respect of this matter.



**BRANCHES :**

**NAVI MUMBAI :** 302 / 304 Arenja Corner, Sector 17, Vashi, Navi Mumbai - 400 703. • Tel. : +91-22-2766 6478  
**DELHI :** 505, Nirmal Tower, 26, Barakhamba Road, New Delhi -110 001. • Tel. : +91-11-4019 0200

**Basis for Qualified conclusion:**

Based on our review and explanation and information provided to us by the Management, deferred tax as per Ind AS 12 is considered on annual basis and hence impact of the same is not ascertainable on the Profit & Loss account and Assets and Liabilities as on 30<sup>th</sup> Sep , 2020.

**Qualified Conclusion:**

Based on our review conducted as above, except for the matter prescribed in the Basis for Qualified Opinion paragraph nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Batliboi & Purohit**  
**Chartered Accountants**  
Firm Registration No.: 101048W



**Raman Hangekar**  
Partner  
Membership No: 030615  
UDIN: 20030615AAAAFU4135



Date: November 12, 2020  
Place: Mumbai